Bionovo, Inc. To Present At The 8th Annual Biotechnology Industry Organization (BIO) CEO & Investor Conference
EMERYVILLE, Calif., Feb. 7 /PRNewswire-FirstCall/ -- Bionovo, Inc. will participate in the 8th Annual BIO CEO & Investor Conference on February 14-15, 2006 at the Waldorf Astoria Hotel in New York. Isaac Cohen, the company's Chairman and Chief Executive Officer, is scheduled to make a presentation on Tuesday, February 14th at 4:30 p.m. EST. Mr. Cohen will then participate in the focus session presentation, titled "Stopping the Vicious Cycle - Apoptosis and Cell Cycle Regulation Treatments," on Wednesday, February 15th at 8:30 a.m. EST. Additional information regarding the conference can be found at www.ceo.bio.org.
To access the live audio webcast or the subsequent archived recording, log on to www.bionovo.com. Please connect to Bionovo's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.
About Bionovo, Inc.
Bionovo is a drug development company focusing on the discovery of novel pharmaceutical agents for cancer and women's health. The company has two drugs ready to enter Phase 2 clinical testing, one for breast cancer therapy and another to treat conditions associated with menopause. The company is developing its products in close collaboration with leading U.S. academic research centers including the University of California, San Francisco; University of Colorado Health Sciences Center; University of California, Berkeley; and University of Texas, Southwestern. For further information please visit: www.bionovo.com.
This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third-party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated, or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission SEC), which are available at www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.Bionovo, Inc.
CONTACT: Jim Stapleton, CFO of Bionovo, Inc., +1-510-601-2000; or VinceDaniels, or James Carbonara, both of Investor Relations, or Janet Vasquez,Public Relations, all at +1-212-825-3210, of Investor Relations Group, forBionovo, Inc.
Web site: http://www.bionovo.com/